What is ARWR's current stock price?

As of now, ARWR is trading at $46.79, with a daily change of +5.72%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

ARWR Stock Analysis & IQ Rating | Arrowhead Pharmaceuticals

ARWR

Arrowhead Pharmaceuticals

$46.79

+$2.53 | +5.72%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$46.92

MKT CAP

$6.47B

52W Low

$9.57

VOL

$2.15M

P/E Ratio

N/A

AVG VOL

$1.97M

RSI

70.06

TREND

Uptrend

ARWR Stock IQ

Login to see Arrowhead Pharmaceuticals (ARWR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

ARWR Target Price

Login to display

Strengths

ARWR Rewards

Earnings are forecast to grow

ARWR Rewards

Upgraded on attractively valued

ARWR Rewards

Outperform the market

Chart

$39.55 (+18.31%)

$22.03 (+112.39%)

$16.79 (+178.68%)

$23.61 (+98.18%)

1year

6month

3month

1month

ARWR Risk Level

ARWR has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

ARWR Analysts Opinion

ARWR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

ARWR Analysts Opinion

ARWR Analysts opinion is positive but there was a setback from the past 3 months

ARWR Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

50%

100%

78%

ARWR Street Sentiment

ARWR Street Sentiment is extremely bullish and have positive views on the near-term outlook

ARWR Performance Sentiment

Sentiments overview associated with ARWR events and the stock performance.

84%

8%

Positive

Negative

32 out of 38
events present

3 out of 38
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$40.45

Resistance
Price

$35.25

Current Price Range

$42.39

Show methods +

Linked to ARWR

IQ

Close Price

Change

NVS

4.27

130.28

+2.95%

SNY

4.02

50.28

+2.30%

ARWR Latest Analysis +

Arrowhead Pharmaceuticals GAAP EPS of -$0.01 in-line revenue of $829.45M beats by $72.01M.

Today

$46.79 | +5.72%

Earnings

A Look Ahead: Arrowhead Pharmas Earnings Forecast. Arrowhead Pharma (NASDAQ:) is gearing up to announce its quarterly earnings on Tuesday 2025-11-25. Here'.s a quick overview of what investors should know before the release.Analysts are estimating that Arrowhead Pharma will report an Investors in Arrowhead Pharma are eagerly awaiting the company'.s announcement hoping for news of surpassing estimates and positive guidance for the next quarter.It'.s worth noting for new investors ...

Mon Nov 24, 2025

$44.26 | +9.42%

Momentum

Goldman Sachs Maintains Arrowhead Pharmaceuticals (ARWR) Neutral Recommendation. Fintel reports that on November 20 2025 Goldman Sachs maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Neutral recommendation. Analyst Price Forecast Suggests 32.59% Upside

Fri Nov 21, 2025

$40.45 | +6.20%

Potential

Rating

Noteworthy Thursday Option Activity: ARWR RBLX COF. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Arrowhead Pharmaceuticals Inc (Symbol: ARWR) where a total volume of 8414 contracts has been traded thus far today a contract volume which is representative o

Thu Nov 20, 2025

$38.09 | -2.26%

Momentum

RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation. Fintel reports that on November 19 2025 RBC Capital maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Outperform recommendation. Analyst Price Forecast Suggests 29.66% Upside

Thu Nov 20, 2025

$38.09 | -2.26%

Potential

Rating

Chardan Capital Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation. Fintel reports that on November 19 2025 Chardan Capital maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Buy recommendation. Analyst Price Forecast Suggests 29.66% Upside

Thu Nov 20, 2025

$38.09 | -2.26%

Rating

Piper Sandler Maintains Arrowhead Pharmaceuticals (ARWR) Overweight Recommendation. Fintel reports that on November 19 2025 Piper Sandler maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Overweight recommendation. Analyst Price Forecast Suggests 29.66% Upside

Thu Nov 20, 2025

$38.09 | -2.26%

Rating

ARWR: REDEMPLO® Approved by FDA for the Treatment of FCS. By Business UpdateREDEMPLO® Approved by FDAOn November 18 2025 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced that the United States Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran) as a treatment for adults suffering from familial chylomicronemia syndrome (FCS). This is the first approved product utilizing Arrowheads TRiM™ platform. The contains no contraindications warnings no necessity for genetically-conf

Wed Nov 19, 2025

$38.97 | -3.71%

Activity

Potential

Arrowhead Scores First FDA Approval With REDEMPLO For Rare Genetic Disorder . (RTTNews) - Arrowhead Pharmaceuticals Inc. (ARWR) announced that the FDA has approved REDEMPLO for adult patients with familial chylomicronemia syndrome.

Wed Nov 19, 2025

$38.97 | -3.71%

Activity

Arrowhead Pharmaceuticals Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome - Slideshow.

Wed Nov 19, 2025

$38.97 | -3.71%

Activity

FAQ About ARWR Stock Insights

What is ARWR current stock price?

What are ARWR stock strengths?

What is ARWR Risk Level?

What is ARWR market cap and volume?

What is ARWR current Stock IQ?

Should I buy ARWR stock right now?

Is ARWR a Strong Buy right now?

What does a 'Strong Buy' rating mean for ARWR?

What does a 'Strong Sell' rating mean for ARWR?

What factors influence ARWR's Stock IQ?

Explore our ARWR Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored ARWR Stock Strategies
Effective Risk Management

FIND US ON

Receive our ARWR Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

ARWR

Arrowhead Pharmaceuticals

Current Price

$46.79

+$2.53 | +5.72%

52W High

$46.92

MKT CAP

$6.47B

52W Low

$9.57

VOL

$2.15M

P/E Ratio

N/A

AVG VOL

$1.97M

RSI

70.06

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

ARWR Rewards

Earnings are forecast to grow

ARWR Rewards

Upgraded on attractively valued

ARWR Rewards

Outperform the market

Linked to ARWR

Symbol

IQ

Close

Change

NVS

4.27

130.28

+2.95%

SNY

4.02

50.28

+2.30%

ARWR Stock IQ

Login to unlock Arrowhead Pharmaceuticals (ARWR) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$39.55 (+18.31%)

$22.03 (+112.39%)

$16.79 (+178.68%)

$23.61 (+98.18%)

1year

6month

3month

1month

ARWR Analysts Opinion

ARWR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

ARWR Analysts Opinion

ARWR Analysts opinion is positive but there was a setback from the past 3 months

ARWR Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

84%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

50%

100%

78%

ARWR Street Sentiment

ARWR Street Sentiment is extremely bullish and have positive views on the near-term outlook

ARWR Risk Level

ARWR has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

ARWR Performance Sentiment

Sentiments overview associated with ARWR events and the stock performance.

84%

8%

Positive

Negative

32 out of 38
events present

3 out of 38
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$40.45

Resistance
Price

$35.25

Current Price Range

$42.39

Show methods +

ARWR Latest Analysis

Arrowhead Pharmaceuticals GAAP EPS of -$0.01 in-line revenue of $829.45M beats by $72.01M.

Today

$46.79 | +5.72%

Earnings

A Look Ahead: Arrowhead Pharmas Earnings Forecast. Arrowhead Pharma (NASDAQ:) is gearing up to announce its quarterly earnings on Tuesday 2025-11-25. Here'.s a quick overview of what investors should know before the release.Analysts are estimating that Arrowhead Pharma will report an Investors in Arrowhead Pharma are eagerly awaiting the company'.s announcement hoping for news of surpassing estimates and positive guidance for the next quarter.It'.s worth noting for new investors ...

Mon Nov 24, 2025

$44.26 | +9.42%

Momentum

Goldman Sachs Maintains Arrowhead Pharmaceuticals (ARWR) Neutral Recommendation. Fintel reports that on November 20 2025 Goldman Sachs maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Neutral recommendation. Analyst Price Forecast Suggests 32.59% Upside

Fri Nov 21, 2025

$40.45 | +6.20%

Potential

Rating

Noteworthy Thursday Option Activity: ARWR RBLX COF. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Arrowhead Pharmaceuticals Inc (Symbol: ARWR) where a total volume of 8414 contracts has been traded thus far today a contract volume which is representative o

Thu Nov 20, 2025

$38.09 | -2.26%

Momentum

RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation. Fintel reports that on November 19 2025 RBC Capital maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Outperform recommendation. Analyst Price Forecast Suggests 29.66% Upside

Thu Nov 20, 2025

$38.09 | -2.26%

Potential

Rating

Chardan Capital Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation. Fintel reports that on November 19 2025 Chardan Capital maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Buy recommendation. Analyst Price Forecast Suggests 29.66% Upside

Thu Nov 20, 2025

$38.09 | -2.26%

Rating

Piper Sandler Maintains Arrowhead Pharmaceuticals (ARWR) Overweight Recommendation. Fintel reports that on November 19 2025 Piper Sandler maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Overweight recommendation. Analyst Price Forecast Suggests 29.66% Upside

Thu Nov 20, 2025

$38.09 | -2.26%

Rating

ARWR: REDEMPLO® Approved by FDA for the Treatment of FCS. By Business UpdateREDEMPLO® Approved by FDAOn November 18 2025 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced that the United States Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran) as a treatment for adults suffering from familial chylomicronemia syndrome (FCS). This is the first approved product utilizing Arrowheads TRiM™ platform. The contains no contraindications warnings no necessity for genetically-conf

Wed Nov 19, 2025

$38.97 | -3.71%

Activity

Potential

Arrowhead Scores First FDA Approval With REDEMPLO For Rare Genetic Disorder . (RTTNews) - Arrowhead Pharmaceuticals Inc. (ARWR) announced that the FDA has approved REDEMPLO for adult patients with familial chylomicronemia syndrome.

Wed Nov 19, 2025

$38.97 | -3.71%

Activity

Arrowhead Pharmaceuticals Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome - Slideshow.

Wed Nov 19, 2025

$38.97 | -3.71%

Activity

Discover ARWR Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of ARWR. We're here to help you make informed investment decisions today.

FIND US ON

Receive our ARWR Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ARWR Stock trends

ARWR Stock performance

ARWR Stock analysis

ARWR investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

ARWR Stock Analysis & IQ Rating | Arrowhead Pharmaceuticals

ARWR Stock IQ

ARWR Target Price

ARWR Risk Level

ARWR Analysts Opinion

ARWR Street Sentiment

ARWR Performance Sentiment

Technical Price Levels

Explore our ARWR Stock insights

Receive our ARWR Daily Alerts

ARWR Stock IQ

ARWR Street Sentiment

ARWR Risk Level

Technical Price Levels

Discover ARWR Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of ARWR. We're here to help you make informed investment decisions today.

Receive our ARWR Daily Alerts

ARWR Runner Alarm